Our Blog

Starpharma signs second oncology agreement with AstraZeneca

03 Jun 2019 – Starpharma (ASX:SPL) has today announced a Development and Option Agreement with AstraZeneca to progress the development (of a Dendrimer Enhanced Product (DEP) version )of an undisclosed AstraZeneca major marketed oncology medicine.


Source: Finance News Network

Share this post